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Abstract
Background: MicroRNAs (miRNAs) are aberrantly expressed in human cancer and involved in the (dys)regulation of cell
survival, proliferation, differentiation and death. Specifically, miRNA-143 (miR-143) is down-regulated in human colon
cancer. In the present study, we evaluated the role of miR-143 overexpression on the growth of human colon carcinoma
cells xenografted in nude mice (immunodeficient mouse strain: N: NIH(s) II-nu/nu).
Methodology/Principal Findings: HCT116 cells with stable miR-143 overexpression (Over-143) and control (Empty) cells
were subcutaneously injected into the flanks of nude mice, and tumor growth was evaluated over time. Tumors arose , 14
days after tumor cell implantation, and the experiment was ended at 40 days after implantation. miR-143 was confirmed to
be significantly overexpressed in Over-143 versus Empty xenografts, by TaqManH Real-time PCR (p,0.05). Importantly, Over-
143 xenografts displayed slower tumor growth compared to Empty xenografts from 23 until 40 days in vivo (p,0.05), with
final volumes of 9286338 and 25126387 mm
3, respectively. Evaluation of apoptotic proteins showed that Over-143 versus
Empty xenografts displayed reduced Bcl-2 levels, and increased caspase-3 activation and PARP cleavage (p,0.05). In
addition, the incidence of apoptotic tumor cells, assessed by TUNEL, was increased in Over-143 versus Empty xenografts
(p,0.01). Finally, Over-143 versus Empty xenografts displayed significantly reduced NF-kB activation and ERK5 levels and
activation (p,0.05), as well as reduced proliferative index, evaluated by Ki-67 immunohistochemistry (p,0.01).
Conclusions: Our results suggest that reduced tumor volume in Over-143 versus Empty xenografts may result from increased
apoptosis and decreased proliferation induced by miR-143. This reinforces the relevance of miR-143 in colon cancer,
indicating an important role in the control of in vivo tumor progression, and suggesting that miR-143 may constitute a
putative novel therapeutic tool for colon cancer treatment that warrants further investigation.
Citation: Borralho PM, Simo ˜es AES, Gomes SE, Lima RT, Carvalho T, et al. (2011) miR-143 Overexpression Impairs Growth of Human Colon Carcinoma Xenografts
in Mice with Induction of Apoptosis and Inhibition of Proliferation. PLoS ONE 6(8): e23787. doi:10.1371/journal.pone.0023787
Editor: Reiner Albert Veitia, Institut Jacques Monod, France
Received June 7, 2011; Accepted July 25, 2011; Published August 25, 2011
Copyright:  2011 Borralho et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by FCT, the Portuguese Foundation for Science and Technology, through grant PTDC/SAU-GMG/099161/2008 (to C.M.P.R.),
postdoctoral fellowships SFRH/BPD/65212/2009 (to P.M.B.) and SFRH/BPD/68787/2010 (to R.T.L.), and PhD fellowship SFRH/BD/60521/2009 (to D.M.S.F). Institute
of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) is an Associate Laboratory of the Portuguese Ministry of Science, Technology and
Higher Education and is partially supported by FCT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cmprodrigues@ff.ul.pt
Introduction
microRNAs (miRNAs or miRs) are endogenously encoded short
non-coding RNAs (20–23 nt), pivotal players in posttranscriptional
gene silencing of target mRNAs. In mammals, incomplete
complementarity binding of the mature miRNA to the 39UTR
of target mRNA results in target gene silencing via translational
repression, or in some cases via mRNA degradation [1].
The strong focus on miRNA research in recent years has lead to
an exponential growth in the number of identified miRNAs, which
exceed 1000 in humans [2] and putatively regulate over 60% of
human genes [3]. Importantly, miRNAs are involved in the
regulation or fine-tuning of a myriad of crucial biological processes
commonly de-regulated in cancer, including cell proliferation,
differentiation, cell-cycle and apoptosis, among others [4,5].
Furthermore, it is now well known that miRNAs are aberrantly
expressed in several forms of human cancer, including colon
cancer [6,7,8]. However, and notwithstanding the fast growth of
knowledge on miRNAs, only a small fraction of the molecular
signaling circuitry regulated by miRNAs is known in cancer.
miR-143 expression has been reported as down-regulated in
colon cancer, both in adenomas [9,10] and colon carcinomas
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23787[6,9], as well as in colon cancer cell lines [11,12]. Further, miR-
143 relevance as a putative cancer biomarker is growing, as it is
down-regulated in various other human cancers, including B-cell
malignancies [13], non-small cell lung cancer [14], esophageal
squamous cell carcinoma [15], esophageal adenocarcinoma [16],
osteosarcoma [17], bladder [18], cervical [19], prostate [20], and
gastric [21] cancer. In addition, miR-143 is considered a pivotal
regulator of gene expression, since it directly targets multiple
mRNAs coding for proteins involved in cell proliferation,
differentiation, survival and apoptosis, including KRAS [22,23],
DNMT3A [24], ELK1 [25], MYO6 [26], Bcl-2 [17] and ERK5
[27]. Interestingly, ERK5 is the most widely reported direct target
of miR-143, which is downregulated by miR-143 overexpression
[11,12]. Finally, growing evidence supports an anti-proliferative,
pro-apoptotic and chemosensitizer role for miR-143 in colon
cancer, since it reduces cell viability and increases sensitivity to 5-
fluorouracil (5-FU), the drug of choice in colorectal cancer
treatment and a known inducer of apoptosis in colon cancer cell
lines [28,29].
Increased expression of mature miR-143 was found to occur
following p53 up-regulation by doxorubicin in HCT116 colon
cancer cells [22], and also in response to 5-FU exposure [12].
Furthermore, miR-143 may be involved in apoptosis proceeding
via the intrinsic and/or extrinsic pathways, since it down-regulates
anti-apoptotic protein Bcl-2, and is up-regulated after Fas-
mediated apoptosis. The latest is accompanied by ERK5
downregulation [27], which we have previously demonstrated to
directly induce apoptosis and chemosensitization in ERK5 siRNA-
mediated knockdown experiments in colon cancer cells [12].
ERK5 is a mitogen-activated protein kinase (MAPK), activated
by a wide range of cellular stresses and mitogens, and involved in
the regulation of cellular survival, differentiation and proliferation.
Importantly, ERK5 targets c-Myc, cyclin D1 and nuclear factor
(NF)-kB, well known cell proliferation regulators [30]. In
particular, NF-kB is involved in the promotion of cell proliferation
and suppression of apoptosis, playing a pivotal role in tumor
progression. NF-kB is constitutively activated in several malignant
cells, including colon cancer [31,32]. Importantly, ERK5
activation of NF-kB is involved in cellular transformation [33]
and is critical for normal progression of the cell cycle from G2-M
and timely mitotic entry [34]. Inhibition of NF-kB activation may
be useful in antitumor therapy by increasing colon cancer cell
sensitivity to 5-FU [35]. In addition, we have recently demon-
strated that miR-143 overexpression significantly increases in vitro
HCT116 colon cancer cell sensitivity to 5-FU, with a marked
decrease in ERK5, NF-kB, and Bcl-2 steady-state levels [12]. This
suggests that miR-143 overexpression in colon cancer cells may be
an important strategy to reduce tumor growth and aggressiveness,
and increase chemotherapy response.
In the present study, we evaluated the role of miR-143
overexpression on growth of HCT116 human colon carcinoma
cells xenografted in mice, and the putative involvement of
apoptosis and proliferation on miR-143 mechanism of action.
Our results show that miR-143 markedly reduces human colon
cancer cell xenograft growth in vivo, causing increased tumor cell
apoptosis and decreased proliferation. In addition, miR-143
overexpression in human tumor xenografts in mice leads to
significantly reduced NF-kB activation, and ERK5 expression and
activation. These results underscore the relevance of miR-143 in
colon cancer, suggesting an important role in the control of tumor
progression in vivo, and expanding its anti-proliferative, pro-
apoptotic and chemosensitizer role that we had previously
demonstrated in vitro.
Results
miR-143 increases HCT116 cell growth inhibition
We initially confirmed the production of mature miR-143 from
the pCR3-pri-miR-143 vector, and the effect of transient miR-143
overexpression from this DNA vector on HCT116 colon
carcinoma cell growth. This was performed by co-transfection of
pCR3-pri-miR-143 (miR-143 expression vector), a firefly lucifer-
ase miR-143 reporter for mature miR-143 detection (miR-143
sensor), and with either miR-143 specific inhibitor (anti-miR-143),
or control (anti-miR-control). pRL-SV40 was also co-transfected
and used as a normalization control. Our results clearly show that
mature miR-143 was expressed from pCR3-pri-miR-143, since
reduction of mature miR-143 bioavailability via anti-miR-143 co-
transfection led to a significant increase in firefly activity
(Figure 1A, left panel, middle bar), as compared to controls
(p,0.05). Importantly, transient miR-143 overexpression signifi-
cantly increased cell growth inhibition (Figure 1A, right panel,
middle bar), compared to empty vector transfected cells (p,0.05),
as evaluated by the MTS metabolism assay.
To evaluate the impact of miR-143 overexpression on the
growth of human colon cancer cells xenografted in mice, we next
produced HCT116 cells with stable miR-143 overexpression (Over-
143) and control cell lines (Empty), by transfection with pCR3-pri-
miR-143 or pCR3-empty, respectively, followed by selection and
propagation of stably transfected cells with G418. Over-143 and
Empty cells with 5 to 25 days of G418 selection were processed for
total RNA extraction to evaluate mature miR-143 expression by
TaqManH Real-time PCR using specific primers for mature miR-
143, and RNU6B for normalization to endogenous control.
Importantly, our results show that high and stable mature miR-
143 expression was consistently obtained in Over-143, as compared
to Empty cells (Figure 1B) (p,0.01).
miR-143 overexpression decreases the growth of HCT116
human colon carcinoma cells xenografted in mice
Having validated our cell model in vitro, we next evaluated the in
vivo effect of miR-143 overexpression on HCT116 tumor xenograft
growth. Over-143 or Empty cell suspensions were injected s.c. into
the flanks of 6-week-old immunodeficient mice, and tumor growth
was evaluated and registered periodically, to plot tumor growth
curves. Tumors arose , 14 days after subcutaneous administra-
tion, and tumorigenicity studies were terminated at day 40 after
cell implantation. Our results demonstrate a significant and
marked reduction of tumor volume in Over-143 xenografts
compared to Empty xenografts, from day 23 after implantation
until the end of the experiment, at day 40 (Figure 2A) (p,0.05 and
p,0.01 from 23 to 30, and from 33 to 40 days after implantation,
respectively). Therefore, Over-143 xenografts showed a significantly
slower tumor growth compared to the Empty xenografts, display-
ing final tumor volumes of 9286338 and 25126387 mm
3,
respectively.
Tumors were collected after sacrificing the animals at the end of
in vivo tumor growth evaluation, 40 days after Over-143 or Empty
cell implantation. Subsequently, total RNA was extracted from
Over-143 and Empty xenografts (t=40), and also from Over-143 and
Empty cells before injection into nude mice (t=0). RNAs were then
used to evaluate mature miR-143 expression. Our results show
that at tumor cell implantation (t=0), miR-143 levels were more
than 200-fold increased in Over-143 compared to Empty cells,
demonstrating that the injected cell lines were in the desired
experimental conditions at implantation (Figure 2B). Importantly,
after 40 days of xenograft growth in vivo, Over-143 xenografts still
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compared to Empty xenografts (p,0.05) (Figure 2B).
miR-143 overexpressing tumor xenografts display
reduced ERK5 steady-state levels, and NF-kB nuclear
translocation
miR-143 directly regulates the expression of several proteins
involved in crucial biological processes, whose deregulation is
commonly associated with cancer. Importantly, transient overex-
pression of miR-143 mimetics in HCT116 [12], SW480 and
DLD-1 [11] colon cancer cell lines has been shown to down-
regulate ERK5 steady-state levels. In addition, modulating mature
miR-143 levels by transient co-tranfection of miR-143 mimetics
and inhibitors regulates ERK5 protein [12]. Furthermore,
activated ERK5 modulates cell survival, differentiation and
proliferation, through c-Myc, cyclin D1 and NF-kB activation
[30]. Therefore, we extracted total proteins from Over-143 and
Empty xenografts (t=40) and from Over-143 and Empty cells prior
Figure. 1. Mature miR-143 overexpression increases cell
growth inhibition. A, HCT116 cells were co-transfected with the
indicated plasmids and anti-miR inhibitors, and analyzed 48 h post-
transfection. Cells were lysed and firefly and renilla luciferase activities
determined by the dual luciferase assay (left panel). Cell growth
inhibition was evaluated by MTS metabolism assays, and cells were
then lysed for dual luciferase assay, to normalize the MTS metabolism
assay (right panel). B, HCT116 cells were transfected with pCR3-pri-miR-
143 and pCR3-empty and selected with G418, to generate Over-143 and
Empty cells, respectively. Cells were harvested for total RNA extraction
after 5 to 25 days of selection. miR-143 expression was evaluated from
1.4 ml cDNA of 10 ng total RNA RT reactions, using specific primers for
miR-143 and RNU6B for normalization. miR-143 expression levels were
calculated by the a ˜a ˜Ct method, using Empty cells as calibrator. Results
are expressed as mean6SEM of at least 3 independent experiments.
*p,0.05 from controls and 1p,0.01 from Empty.
doi:10.1371/journal.pone.0023787.g001
Figure. 2. miR-143 overexpression decreases human colon
carcinoma cell tumor xenograft growth in nude mice. Forty-
eight hours after release from dual-thymidine block, 5610
5 miR-143
overexpressing (Over-143), or control (Empty) cells, were s.c. injected
into the flanks of nude mice. A, Tumor xenograft size was regularly
measured (every 2-3 days), from the initial signs of tumor development,
until the end of the experiment (, 14 and 40 days after cell
implantation, respectively), to plot tumor growth curves. Animals were
then sacrificed and tumors excised. B, Total RNA was extracted from
Over-143 and Empty cells prior to implantation into animals (t=0 days)
and from snap frozen tumor xenograft samples (t=40 days), and used
to quantify mature miR-143 expression. miR-143 expression was
evaluated from 1.4 ml cDNA of 10 ng total RNA RT reactions, using
specific primers for miR-143 and RNU6B for normalization. miR-143
expression levels were calculated by the a ˜a ˜Ct method, using Empty cells
as calibrator. Two independent experiments were performed using a
total of 12 animals for Over-143 and 10 animals for Empty. Results are
expressed as mean6SEM. *p,0.05, 1p,0.01 from Over-143 and
{p,0.05 from Empty.
doi:10.1371/journal.pone.0023787.g002
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steady-state levels by Western blot (Figure 3, top). Our results
demonstrate that Over-143 xenografts displayed reduced ERK5
protein levels compared to Empty xenografts (Figure 3, bottom left)
(p,0.05). Furthermore, we also evaluated p-ERK5, the dual
phosphorylated (Thr218/Tyr220) active form of ERK5. Over-143
xenografts presented reduced p-ERK5 compared to Empty
xenografts, which resulted in decreased ratios of p-ERK5/total
ERK5 (Figure 3, bottom right) (p,0.05).
Evidence suggests that ERK5 activation of NF-kB promotes
cellular transformation [33], and that NF-kB is a critical factor for
G2–M cell cycle progression and timely mitotic entry [34]. NF-kB
is also involved in inhibition of apoptosis and stimulation of
cellular growth, thus contributing to tumor promotion, and
chemoresistance. Curiously, our results indicate that NF-kB
steady-state levels were increased in Over-143 xenografts at day
40, compared to Empty xenografts (Figure 4A, bottom left)
(p,0.01). Nevertheless increased steady-state levels of IkBi n
Over-143 versus Empty xenografts at day 40 (Figure 4A, bottom
right) (p,0.05) suggest that NF-kB is less activated in Over-143
xenografts. This was further confirmed by the reduced ratio
between nuclear and cytoplasmic NF-kB levels in Over-143
compared to Empty xenografts (Figure 4B) (p,0.05).
miR-143 overexpressing tumor xenografts display
increased apoptosis and reduced proliferation
Our results demonstrate that miR-143 overexpression increased
colon tumor cell growth inhibition in vitro, and decreased the
growth of tumor cells xenografted in mice. In addition, miR-143
overexpresion reduced ERK5 steady-state levels, ERK5 activa-
tion, and NF-kB nuclear translocation, suggesting regulation of
colon cancer cell survival, and proliferation capabilities. Impor-
tantly, we and others have previously reported that ERK5
knockdown by RNA interference induces apoptosis in vitro
[12,36]. We next evaluated the effect of miR-143 on apoptosis
and proliferation of human tumor xenografts in mice. Over-143
Figure. 3. miR-143 overexpression decreases ERK5 expression
and activation in tumor xenografts. Total proteins were extracted
from Over-143 and Empty cells prior to implantation into animals (t=0
days) and from snap frozen tumor xenograft samples (t=40 days), and
used to evaluate ERK5 and p-ERK5 steady-state levels by Western blot.
Results are expressed as mean6SEM. *p,0.05 from Empty.
doi:10.1371/journal.pone.0023787.g003
Figure. 4. miR-143 overexpression decreases NF-kB nuclear
translocation in tumor xenografts. A, Total proteins were extracted
from Over-143 and Empty cells prior to implantation into animals (t=0
days) and from snap frozen tumor xenograft samples (t=40 days), and
used to evaluate NF-kB and IkB steady-state levels by Western blot. B,
cytosolic and nuclear proteins were extracted from snap frozen tumor
xenograft samples (t=40 days; Over-143 and Empty), to evaluate NF-kB
nuclear translocation by Western blot. Results are expressed as
mean6SEM. *p,0.05 and 1p,0.01 from Empty.
doi:10.1371/journal.pone.0023787.g004
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apoptotic protein Bcl-2 (Figure. 5A) (p,0.05), together with
increased caspase-3 processing and PARP cleavage (Figure. 5B
and C) (p,0.05). As expected, the frequency of TUNEL-positive
cells was increased in Over-143 versus Empty xenograft tumoral
tissue, which displayed 3.860.2 and 2.260.1 cells per 10
3 mm
2 of
tumor area, respectively (Figure. 6A) (p,0.01). This data re-
enforce the notion that induction of apoptosis is part of the in vivo
mechanism of action of miR-143 in this xenografted tumor model.
Importantly, immunohistochemistry for Ki-67 in xenograft tissue
sections showed that the fraction of proliferating cells is lower in
Over-143 versus Empty xenografts, with percentages of proliferation
of 40.66 1.1 and 63.760.9%, respectively (Figure. 6B) (p,0.01).
Thus, miR-143 overexpression induces apoptosis and reduces
proliferation of human colon carcinoma cells xenografted in mice,
further re-enforcing the potential deleterious effects arising from
loss of miR-143 expression in human colon cancer.
Discussion
The relevance of miRNAs in human cancer is growing
exponentially, with this class of small non-coding RNAs
considered pivotal gene expression regulators, and carrying
enormous potential as diagnostic, prognostic and therapeutic
tools. Aberrant miRNA expression may negatively impact on the
regulation of multiple important cellular processes, such as cell
proliferation, differentiation and turnover, commonly de-regulated
events in cancer. In particular, miR-143 is gaining increasing
relevance as putative cancer biomarker and therapeutic tool in
human cancer. Its reduced expression has been demonstrated in
multiple cancer types, including those of the gastrointestinal tract.
In addition to colon cancer, miR-143 has been reported down-
regulated in oesophageal squamous cell carcinoma [15], oesoph-
ageal adenocarcinoma [16], and gastric cancer [21]. Further, we
and others have previously demonstrated that miR-143 expression
is reduced in human colon cancer [6,7,10], and also that miR-143
overexpression markedly reduces the viability of several colon
cancer cell lines in vitro [11,12]. In the present study, we evaluated
the effect of miR-143 overexpression on HCT116 human colon
cancer tumor xenograft growth in nude mice.
Initially, we demonstrated transient miR-143 overexpression
from pCR3-pri-miR-143 in HCT116 cells, which significantly
increased cell growth inhibition as compared to pCR3-empty
transfection, in accordance with our previous results [12]. To
evaluate the in vivo effect of miR-143 overexpression on colon
cancer tumor xenograft growth, we next created HCT116-derived
stable miR-143 overexpressing cells, and confirmed in at least
three independent batches evaluated at multiple random selection
times that miR-143 expression was consistently highly increased in
Over-143 versus Empty cells, attesting to the robustness of miR-143
overexpression in our cell model. Such a high differential
expression has not been reported before for miR-143 in human
colon cancer samples. However, a recent report in ulcerative
colitis patients, which are at increased risk for development of
colorectal cancer, demonstrated that miR-143 expression is
downregulated up to 20-fold, compared to normal colon [37].
Several other reports have shown differential miRNA expression
of . 100-fold in biological samples using different miRNA
detection methods and models [38,39,40,41,42,43]. Importantly,
we have also shown that miR-143 expression is 100-fold lower in
SW480 as compared to HCT116 cells [12]. In addition, higher
levels of miRNA overexpression can be achieved, without a
corresponding effect on cell viability, or other cellular functions
[44].
Stable miR-143 overexpression significantly decreased the rate
of xenografted tumor growth, as clearly evidenced by the reduced
Over-143 tumor xenograft volumes as compared to Empty. Further,
tumor xenografts from Over-143 and Empty cells were first
detectable 14 days after cell implantation. In the following week,
the impairment of tumor growth in result of miR-143 overex-
pression was already evident, becoming statistically significant 9
days later, at 23 days after cell implantation. Our results clearly
demonstrate that miR-143 overexpression in colon cancer cells,
delays xenografted tumor growth, highlighting the relevance of
miR-143 as a putative therapeutic agent for the treatment of this
disease. Interestingly, this is in agreement with a recent study using
prostate cancer cell lines, in which repeated xenograft intratu-
moral injection (3x) of miR-143 mimetics at 5000 nM, followed by
in vivo electroporation, resulted in tumor growth abrogation or
decrease, in mice grafted with LNCaP and C4-2 prostate cancer
cells, respectively [20]. Mature miR-143 expression was increased
from 1 to 3 fold in LNCaP and C4-2 xenografts. Here, we
demonstrate that we are able to maintain higher levels of mature
miR-143 expression throughout the xenografted tumor growth
evaluation period, by transfecting HCT116 cells in vitro and
selecting with G418 prior to subcutaneous injection, which
resulted in a marked decrease in colon cancer xenograft tumor
growth. Our results are also in line with another recent study
where liposome entrapped 39-modified miR-143 mimetics were
administered by intravenous injection following a regimen of
weekly administration (5x), in mice xenografted with human DLD-
1 colon cancer tumors [9]. The authors reported a higher stability
of the miR-143 mimetics to nuclease degradation and a significant
dose-dependent decrease in tumor xenograft size in modified-miR-
143 treated mice as compared to control miRNA (non-specific
sequence), with a final tumor xenograft size reduction of , 50%
two weeks after the five week treatment at a dose of 50 mg per
mouse.
ERK5 is the most widely reported miR-143 direct target in
colon cancer, and ERK5 signaling is involved in the regulation of
cell survival, differentiation, proliferation and apoptosis. Our
results demonstrated a significant reduction in ERK5 and p-
ERK5 in Over-143 versus Empty xenografts. This suggests that in
human colon cancer cell tumor xenografts, ERK5 is targeted by
miR-143, leading to reduced protein steady-state levels and
activation. These results further expand previous reports of miR-
143-mediated ERK5 expression knockdown in colon cancer cell
lines in vitro [11,12], and are in agreement with reduced ERK5
expression following repeated (3x) miR-143 intratumoral injection
and in vivo electroporation in prostate cancer cell tumor xenografts
[20]. In addition, ERK5 activates multiple cellular proteins
involved in the regulation of cell proliferation and survival,
including NF-kB. ERK5 activation of NF-kB appears to be an
extremely relevant biological event, since it has been implicated in
cellular transformation [33], cell cycle progression from G2 to
mitosis, and timely mitotic entry [34]. Curiously, our results show
that Over-143 xenografts displayed increased expression of NF-kB,
compared to Empty xenografts. However, we also found increased
expression of IkBi nOver-143 versus Empty xenografts, suggesting
that NF-kB may not be increasingly activated. In fact, reduced
NF-kB nuclear translocation in Over-143 versus Empty xenografts
confirmed a significant reduction of NF-kB activation. This
suggests that miR-143 overexpression diminishes ERK5 expres-
sion and activation, which in turn may lead to reduced NF-kB
activation, thus reducing tumor cell proliferation and growth in
this in vivo tumor model. This is also supported by previous studies,
where shRNA-mediated ERK5 knockdown in T lymphoma cell
line EL-4 decreased nuclear accumulation of the NF-kB p65
miR-143 and Growth of Colon Carcinoma Xenografts
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localization of p65 and increased activation [45]. Further,
stimulation of ERK5 was shown to activate NF-kB via ribosomal
S6 kinase 2 (RSK2)-mediated phosphorylation, and degradation of
IkB [34]. In addition, nuclear translocation of NF-kB is greater in
proliferative compared to resting phase colon cancer cells [31].
Importantly, ERK5 knockdown abrogated the growth of EL-4
subcutaneous tumors in mice [45]. In addition, the ERK5/NF-kB
axis may be an important signaling pathway in mediating
sensitivity to anti-cancer drugs. Similar to the effects we reported
after exposure of HCT116 colon cancer cells overexpressing miR-
143 to 5-fluorouracil [12], exposure of MDA-MB-231 breast
cancer cells to genistein induced cell growth suppression and
induction of apoptosis, with down-regulation of ERK5, p-ERK5,
NF-kB and Bcl-2 steady state levels. Interestingly, genistein
exposure markedly reduced NF-kB DNA binding activity, via
MEK5/ERK5 pathway inhibition [46], which raises the possibil-
ity that miR-143 may also be involved in genistein mechanism of
cytotoxicity. Collectively, these data underscore the relevance of
ERK5/NF-kB signaling for xenografted tumor proliferation and
growth, and highlight the pivotal role of miR-143 in the regulation
of this molecular signaling pathway. The early loss of miR-143
expression in the transition of normal colon to adenoma [9], may
be a key event in colon cancer tumorigenesis by allowing
unchecked cell proliferation, and this may also contribute to
tumor growth and progression.
Another important aspect of miR-143 allowing the control of
tumor growth may be its putative pro-apoptotic role. In this
Figure. 5. miR-143 overexpression reduces Bcl-2, and increases caspase-3 processing and PARP cleavage in tumor xenografts. Total
proteins were extracted from Over-143 and Empty cells prior to implantation into animals (t=0 days) and from snap frozen tumor xenograft samples
(t=40 days), and used to determine by Western blot: A, steady state levels of Bcl-2; B, active caspase-3; and C, PARP cleavage. Results are expressed as
mean6SEM. FL, full length. *p,0.05 from Empty.
doi:10.1371/journal.pone.0023787.g005
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significantly decreases the steady-state levels of anti-apoptotic
protein Bcl-2 [12,17], inducing apoptosis and sensitization to Fas-
induced apoptosis [27]. In addition, we have also shown that miR-
143 induces sensitization of HCT116 colon cancer cell line to 5-
fluorouracil-induced apoptosis [12], which in turn is Fas-
dependent in this cell type [28]. Here, we show that Over-143
versus Empty xenografts displayed decreased steady-state levels of
Bcl-2, and increased caspase-3 activation and PARP processing,
suggesting that miR-143 overexpressing xenografts may present
higher levels of tumor cell apoptosis.
Finally, to confirm the indications that miR-143 may reduce
tumor xenograft growth by reducing proliferation and increasing
apoptosis of colon cancer cells, we evaluated apoptosis and
proliferation in tumor xenograft tissue sections, by TUNEL assay
and Ki-67 immunohistochemistry, respectively. Importantly, miR-
143 overexpression significantly increased apoptosis, and de-
creased proliferation, which is consistent with the marked
reduction in tumor growth. To our knowledge, this is the first
demonstration that miR-143 overexpression induces apoptosis in
human colon tumor cells xenografted in mice, and are in
agreement with reported decreased proliferation ratio of LNCaP
and C4-2 prostate cancer xenograft tumors injected with miR-143
and electroporated in vivo [20].
The results presented herein provide additional knowledge on
miR-143 mechanism of action in human colon tumor cells
xenografted in mice. miR-143 overexpression resulted in reduced
tumor xenograft growth, with tumors presenting decreased
proliferation and increased apoptosis. The mechanism of miR-
143 action in this model is suggested to involve modulation of
ERK5/NF-kB signaling pathways. Collectively, our data re-
enforces the notion that miR-143 loss may be a pivotal event in
colon cancer, suggesting an important function for miR-143 in the
control of tumor progression in vivo. Additional studies are needed
Figure. 6. miR-143 overexpression increases apoptosis and decreases proliferation in tumor xenografts. Tumor xenografts obtained by
s.c. injection of Over-143 or Empty cells were formalin fixed and paraffin embedded. Four and 3-mm-thick sections were cut and used for TUNEL assay
and Ki-67 immunohistochemistry, respectively. A, Analysis of in situ detection of apoptotic cells in tumor sections of Over-143 and Empty xenografts.
Representative images of TUNEL assay (100x) (left panel), and number of TUNEL-positive cells (right panel) of Over-143 and Empty xenografts. B,
Analysis of cell proliferation by Ki-67 immunostaining in tumor sections of Over-143 and Empty xenografts. Representative images of Ki-67
immunostaining (400x) (left panel), and percentage of Ki-67-positive cells (right panel) of Over-143 and Empty xenografts. Results are expressed as
mean6SEM. 1p,0.01 from Empty.
doi:10.1371/journal.pone.0023787.g006
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cells, as this may prove to be a valid a therapeutic approach for
colon cancer treatment.
Materials and Methods
Ethics statement
All experimental procedures were carried strictly within the rules of
the Portuguese official Veterinary Directorate (Direcc ¸a ˜o Geral de
Veterina ´ria, DGV), which follows the FELASA (Federation of
European Laboratory Animal Science Associations) guidelines and
recommendations concerning laboratory animal welfare. In this
regard, animal experiments at IPATIMUP, University of Porto
complied with the European Union legislations governing animal
experimentation, namely the Convention for the Protection of
Vertebrate Animals used for Experimental and other Scientific
Purposes (ETS123), the EC recommendation nu 2007/526/CE and
the Directive for the Protection of Vertebrate Animals used for
Experimental and other Scientific Purposes (86/609/EEC), which
was transposed to the National Laws through Decreto-Lei nu 129/92.
Experiments further complied with the remaining national legislation
for animal protection and welfare, namely Portaria nu 1005/92,
Portaria nu466/95, Decreto-Lei nu197/96, and Portaria nu1131/97.
Cell culture
HCT116 human colorectal cancer cells [47] were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (Invitrogen Corporation, Grand Island, NY)
and 1% antibiotic/antimycotic solution (Sigma-Aldrich, St. Louis,
MO),and maintained at 37uC ina humidified atmosphere of 5%CO2.
Transfection of miR-143 vectors and anti-miR-143
inhibitor
HCT116 cells were transiently transfected with miR-143 overex-
pression vector, coding for the miR-143 precursor (pCR3-pri-miR-
143), and miR-143 sensor,comprising two sequences complementary
to mature miR-143 sequence (pGL3-miR-143 sensor) [48]. pRL-
S V 4 0( P r o m e g a ,M a d i s o n ,W I )w a su s e df o rt r a n s f e c t i o nn o r m a l i -
zation. pGL3-control plasmid (Promega) and pCR3-empty vector
were used as negative controls. To further validate the experimental
model, cells were co-transfected with anti-miR inhibitors, by adding
50 nM anti-miR-143 or anti-miR-control inhibitors (Applied Biosys-
tems, Foster City, CA) to the vector mixture described above.
Transfections were performed using lipofectamine 2000 (Invitrogen),
according to the manufacturer’s instructions.
Evaluation of cell growth inhibition
Cell growth inhibition was evaluated with CellTiter96H
AQueous Non-Radioactive Cell Proliferation Assay (Promega),
using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium inner salt (MTS), according to
the manufacturer’s instructions. Finally, cells were processed for
luciferase assay and transfection efficiency normalization.
Luciferase activity
Firefly and renilla luciferase activities were measured using the
Dual-LuciferaseH Reporter Assay System (Promega). Renilla
luciferase activity was used as a transfection normalization control.
Generation of HCT116 cells with stable expression of
miR-143
miR-143 overexpression and control cell lines were prepared
from HCT116 cells as previously described [12]. Briefly, , 80%
confluent HCT116 cells were trypsinized, counted and plated on 6
well plates at a density of 1.5610
5 cells/well. Twenty-four hours
after plating, cells were transfected with 4 mg of miR-143
expression vector (pCR3-pri-mir-143) [48] or 4 mg of the
respective empty vector control (pCR3-empty), using lipofecta-
mine 2000 (Invitrogen), according to the manufacturer’s instruc-
tions, to originate Over-143 and Empty cell lines, respectively.
Twenty four hours later, selection of transfected cells with 1 mg/
ml G418 (Invitrogen) was initiated, with transfected cell popula-
tions being propagated and maintained by splitting sub-confluent
cells into fresh complete media supplemented with 1 mg/ml
G418, every 3 days. After three weeks of selection, miR-143
expression was evaluated by TaqManH Real-time RT-PCR; after
confirming miR-143 overexpression in Over-143, cells were
xenografted in mice for evaluation of tumor growth in an in vivo
model. In our previous in vitro studies, we have used a single clone
with miR-143 overexpression in parallel with a miR-143
overexpressing cell population [12], similar to the one used in
the present study. All reported effects were similar in both
overexpression cell lines as compared to controls, with no marked
changes in the effects from the miR-143 overexpression single
clone cell line to the miR-143 overexpression cell population.
Processing of cells for xenograft tumor growth
evaluation
Prior to animal injection, cells were synchronized by dual-
thymidine block as previously described [12]. Briefly, sub-
confluent cell populations were trypsinized, counted, and plated
on T150 flasks, at a density of 1.5610
5 cell/ml, using 20 ml
complete media supplemented with 1 mg/ml G418. Eight hours
after plating, 2 mM thymidine (Sigma-Aldrich) in ddH20 was
added to the culture media, and cells were cultured for 14 h. Cells
were then released from first thymidine block by removing culture
media, washing 3 times with PBS and by adding fresh complete
media supplemented with 1 mg/ml G418, without thymidine.
Ten hours later, cells were submitted to a second thymidine block,
by replacing culture media with complete media supplemented
with 1 mg/ml G418 and 2 mM thymidine. Fourteen hours later,
cells were released from second thymidine block by removing
culture media, washing 3 times with PBS and by adding fresh
complete media supplemented with 1 mg/ml G418, without
thymidine. Cells were grown for additional 48 h, prior to animal
injection.
Xenograft growth evaluation
Forty-eight hours after release from second block, cells were
washed 3 times with PBS, trypsinized, counted and ressupended in
DMEM at a density of 5610
6 cells/ml DMEM for animal
injection. A total of 5610
5 Over-143 or Empty cell line suspension
(100 ml cell suspension), was injected subcutaneously into the
flanks of 6-week-old immunodeficient nude mice (strain N:NIH(-
S)II-nu/nu). Two independent experiments were performed, using
a total of 12 animals for Over-143 and 10 animals for Empty tumor
xenograft growth evaluation. From the moment of injection,
animals were inspected regularly for signs of tumor development,
and the size of the tumors regularly measured with calipers every
2-3 days, recorded in an individualized chart, and used to calculate
tumor volumes (WxLxH). Tumorigenicity studies in mice with
subcutaneous tumors were terminated at day 40 after subcutane-
ous injection of cells, when mice were sacrificed. At excision,
tumors were sectioned into two equal portions; one half was fixed
overnight in 10% buffered formalin for subsequent paraffin
embedding and sectioning; the other half was rinsed with sterile
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subsequent RNA and protein extraction.
Total RNA extraction
Tissue from tumor xenografts was used for RNA extraction,
together with cell pellets from Over-143 and Empty cells prior to
injection into nude mice (t=0). Total RNA containing small RNA
species was extracted from tissues and cell lines with TRIZOLH
reagent (Invitrogen) according to the manufacturer’s instructions.
Samples were homogenized in TRIZOLH reagent using a motor-
driven Bio-vortexer (No1083; Biospec Products, Bartlesfield, OK)
and disposable RNAse/DNAse free sterile pestles (Thermo Fisher
Scientific, Inc., Chicago, IL). RNA was quantified using a
NanoDropH spectrophotometer, and typically showed A260/280
ratios between 1.9 and 2.1.
Mature miR-143 expression
Real-time PCR was performed to determine the expression level
of mature miR-143, as previously described [12]. RT reactions
were performed using 20 ng of total RNA extracted from tumor
xenografts and also from cell lines prior to injection into the nude
mice (t=0), using a TaqManH MicroRNA reverse transcription kit
and TaqManH MicroRNA assays specific for the mature form of
hsa-miR-143, and human RNU6B for normalization to endoge-
nous control. Real-time PCR reactions were performed using
standard TaqManH PCR reagents and TaqManH MicroRNA
assays for hsa-miR-143, and human RNU6B (all from Applied
Biosystems). Triplicate reactions were run per sample. Data were
collected with 7000 System Sequence Detection Software, version
1.2.3 (Applied Biosystems). The comparative threshold cycle
method was used to calculate the amplification factor, where the
threshold cycle (Ct) is defined as the cycle number at which the
fluorescence passes the fixed threshold intensity level. miR-143
expression levels in different samples were calculated on the basis
of DDCt method. Empty cells prior to injection into nude mice were
used as the calibrator. The n-fold change in miR-143 expression
was obtained using the formula: 2
-DDCt.
Total, nuclear and cytosolic protein isolation
Total protein extracts were prepared from tumor xenograft
tissues and cell lines. Samples were homogenized in ice-cold buffer
containing 10 mM Tris-HCl, pH 7.6, 5 mM MgCl2, 1.5 mM
KAc, 2 mM dithiothreitol (DTT) and protease inhibitor cocktail
tablet (Roche Diagnostics GmbH, Mannheim, Germany), for 15
sec/tube using a motor-driven Bio-vortexer and disposable sterile
pestles. Subsequently, an equal volume of ice-cold 2X total protein
buffer, containing 10 mM Tris-HCl pH 7.6, 1% Nonidet-P40 and
protease inhibitor cocktail tablet was added, and the samples were
homogeneized by vortexing and incubated on ice for 30 min.
Next, samples were sonicated for 30 sec and centrifuged at
10,000 g for 10 min, with total proteins being recovered in the
supernatants. Total protein extracts were snap frozen in liquid
nitrogen and stored at -80uC.
To evaluate nuclear translocation of NF-kB, cytoplasmic and
nuclear extracts were prepared from tumor xenograft tissues.
Samples were homogenized as described above for total protein
extraction, and next centrifuged at 500 g for 10 min at 4uC.
Cytosolic proteins were recovered in the supernatant. Nuclear
pellets were washed in buffer containing 10 mM Tris-HCl,
pH 7.6, 5 mM MgCl2, 0.25 M sucrose, 0.5% Triton X-100,
and protease inhibitors, and then centrifuged at 500 g, resus-
pended, and sonicated in buffer containing 10mM Tris-HCl,
pH 7.6, and 0.25 M sucrose with protease inhibitors. Finally, the
suspension was centrifuged through 0.88 M sucrose at 2000 g for
20 min at 4uC, and nuclear proteins recovered in the supernatant.
Immunoblotting
Steady-state levels of Bcl-2, caspase-3, PARP, ERK5, p-ERK5,
NF-kB (p65), IkB, GAPDH and histone H3 proteins were
determined by immunoblot analysis. Briefly, 50-75 mg of total
protein extracts were separated on 6, 8 or 12% SDS-polyacryl-
amide electrophoresis gels. After electrophoretic transfer onto
nitrocellulose membranes, immunoblots were incubated with 15%
H2O2 for 15 min at room temperature. After blocking with 5%
milk solution, the blots were incubated overnight at 4uC with
primary mouse monoclonal antibody reactive to Bcl-2 (#sc-7382)
and GAPDH (#sc-32233), or with primary rabbit polyclonal
antibody reactive to caspase-3 (#sc-7148), PARP (#sc-7150), NF-
kB (p65) (sc-372), or to IkB (sc-371) (all from Santa Cruz
Biotechnology, Inc., Santa Cruz, CA). Blots were also incubated
overnight at 4uC with primary rabbit polyclonal antibody reactive
to ERK5, p-ERK5 (#3372 and #3371; Cell Signaling, Beverly,
MA) or to histone H3 (#06-755; Millipore, Billerica, MA). Finally,
the immunoblots were incubated with secondary anti-mouse or
anti-rabbit sera conjugated with horseradish peroxidase (Bio-Rad
Laboratories, Hercules, CA) for 3 h at room temperature. The
membranes were processed for protein detection using Super
Signal
TM substrate (Pierce, Rockford, IL,) to visualize proteins of
interest by chemoluminescence. b-actin was used as a loading
control, using a primary mouse antibody reactive to b-actin (#A-
5441; Sigma-Aldrich). Protein concentrations were determined
using the Bio-Rad protein assay kit according to the manufactur-
er’s instructions.
Tumor processing for histological sections
Tumors fixed in 10% buffered formalin were embedded in
paraffin, using a tissue processor. Tumor samples were kept for
90 min in 70%, 95% and absolute ethanol, xylol and paraffin, and
then remained in paraffin (70uC) until paraffin inclusion. The
paraffin-embedded routine tissue blocks were stored at 4uC. Three
and 4 mm-thick sections were cut from paraffin blocks onto
superfrost ultra plus slides (Menzel-Glaser, Braunschweig, DE), for
later use in Ki-67 immunohistochemistry and DNA fragmentation
assay, respectively.
In situ detection and quantitation of apoptosis
Apoptotic cells were quantitated in tumor tissue sections using
the transferase mediated deoxyuridine triphosphate (dUTP)-
digoxigenin nick-end labeling (TUNEL) assay [ApopTagH Red
for indirect immunofluorescence staining kit (#S7165 Chemi-
con)], following the manufacturer’s instructions. Specimens were
then counterstained with Hoechst 5 mg/ml, for 10 min, at room
temperature. Finally, slides were rinsed, dehydrated and a glass
coverslip was mounted using Fluoromount-GTM mounting media
(Beckman Coulter Inc., Fullerton, CA). The specimens were
examined using a bright field microscope using a Axio Scope A.1
fluorescence microscope (Zeiss Axioskop; Carl Zeiss GmbH, Jena,
Germany). Images were acquired, under a 100x magnification,
using a DFC490 camera (Leica Microsystems AG, Heersbrugg,
Switzerland) with the IM50 software for image acquisition (Leica
Microsystems, version 1.20, Release 9). Positive apoptotic cells
were detected, and their frequency compared within the different
samples. Apoptosis index was evaluated in tumor section images at
100x, only being considered areas with dense tumor cell mass,
displaying similar cell density between Over-143 and Empty
xenografts. Quantitation of TUNEL positive cells and tumor area
were performed using Image J software (http://rsbweb.nih.gov/ij/
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10
3 mm
2 of tumor tissue.
Immunohistochemistry for Ki-67 expression
Immunostaining was performed by the peroxidase-indirect-
polymer method. Tumor tissue sections were deparaffinized,
rehydrated and subjected to epitope antigen retrieval (20 min,
94uC) with target retrieval solution high pH 50x Dako Envision
TM
Flex (DAKO A/S, Glostrup, Denmark) in a pre-treatment module
PTlink (Dako, Model PT 10130). Primary monoclonal mouse
antibody anti-human KI67 (Clone MIB-1, #M7240; Dako) at
1:300 was used. Immunohistochemistry was performed using an
automated stainer (Dako Autostainer, Link 48) by the peroxidase-
indirect-polymer method (#K8000, Dako) for Ki-67. Tonsil was
used as positive control. For negative controls, the primary
antibody was omitted during the staining. Proliferation was
evaluated in tumor section images at 400x, only considering areas
with dense tumor cell mass, displaying similar cell density between
Over-143 and Empty xenografts. Quantitation of Ki-67 positive cells
was performed using Image J software. Proliferation was expressed
as percentage of Ki-67-positive cells.
Densitometry and statistical analysis
The relative intensifies of protein bands were analyzed using the
densitometric analysis program Quantity One version 4.6 (Bio-
Rad Laboratories). All data are expressed as the mean6SEM of
similar samples, from two independent experiments. Statistical
significance was evaluated using the Student’s t-test. Values of
p,0.05 were considered statistically significant.
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